Venrock Healthcare Capital Partners II, L.P.

CIK 1602264 · last filed 2022-10-06

Venrock Healthcare Capital Partners II, L.P. is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider bought $26.3M of TCDA on Oct 6, 2022. Across all open-market trades the lifetime net is +$86.5M, making them a net buyer over the disclosed history. The firm reports its address in New York, NY. 45 SEC filings were submitted jointly with VHCP Co-Investment Holdings II, LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

2

Total Filings

3

Lifetime Open-Market Net

$86.46M

Filer Profile

Reported Address

7 BRYANT PARK
23RD FLOOR
NEW YORK, NY 10018

Phone

(650) 475-3734

State of Incorporation

Related Filers

VHCP Co-Investment Holdings II, LLC — 45 joint filings, latest 2022-10-26

Bong Y Koh — 44 joint filings, latest 2022-10-26

Nimish P Shah — 36 joint filings, latest 2022-10-26

VHCP Co-Investment Holdings III, LLC — 33 joint filings, latest 2022-10-26

VHCP Management III, LLC — 33 joint filings, latest 2022-10-26

VHCP Management EG, LLC — 23 joint filings, latest 2022-10-26

Venrock Healthcare Capital Partners EG, L.P. — 23 joint filings, latest 2022-10-26

Anders D Hove — 1 joint filings, latest 2015-06-17

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Tricida, Inc. (TCDA) Delisted	10%+ Owner	9,541,900	$0.11	$1.03M	$77.36M	2	2022-10-06
Cogent Biosciences, Inc. (UMRX) Delisted	10%+ Owner	4,004,273	—	—	$9.10M	1	2020-08-18

Recent Filings

3 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2022-10-06	Tricida, Inc. (TCDA) Delisted	Buy (P)	+2,231,000	$26.35M	EDGAR
2022-06-24	Tricida, Inc. (TCDA) Delisted	Buy (P)	+4,920,200	$51.01M	EDGAR
2020-08-18	Cogent Biosciences, Inc. (UMRX) Delisted	Buy (P)	+3,608,000	$9.10M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.